Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole‐body …

M Salvatori, G Perotti, V Rufini… - Clinical …, 2004 - Wiley Online Library
Summary objective To evaluate the risk of performing inappropriate 131I ablative therapies
for thyroid carcinoma in patients lacking thyroid remnants or metastases, using a strategy of …
被引用次数：36 相关文章

Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan …

M Salvatori, G Perotti, V Rufini… - Clinical …, 2004 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the risk of performing inappropriate (131) I ablative therapies for
thyroid carcinoma in patients lacking thyroid remnants or metastases, using a strategy of …

[引用][C] Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole …

M SALVATORI, G PEROTTI, V RUFINI… - Clinical …, 2004 - pascal-francis.inist.fr
Are there disadvantages in administering 131I ablation therapy in patients with differentiated
thyroid carcinoma without a preablative diagnostic 131I whole-body scan? CNRS Inist …

Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan …

M Salvatori, G Perotti, V Rufini, ML Maussier… - Clinical …, 2004 - europepmc.org
Objective To evaluate the risk of performing inappropriate (131) I ablative therapies for
thyroid carcinoma in patients lacking thyroid remnants or metastases, using a strategy of …